Cargando…

Systematic review of models assessing the economic value of routine varicella and herpes zoster vaccination in high-income countries

BACKGROUND: A systematic review was conducted to assess the cost-effectiveness of routine varicella and herpes zoster (HZ) vaccination in high-income countries estimated by modelling studies. METHODS: A PubMed search was performed to identify relevant studies published before October 2013. Studies w...

Descripción completa

Detalles Bibliográficos
Autores principales: Damm, Oliver, Ultsch, Bernhard, Horn, Johannes, Mikolajczyk, Rafael T., Greiner, Wolfgang, Wichmann, Ole
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2015
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4455277/
https://www.ncbi.nlm.nih.gov/pubmed/26041469
http://dx.doi.org/10.1186/s12889-015-1861-8
_version_ 1782374733993476096
author Damm, Oliver
Ultsch, Bernhard
Horn, Johannes
Mikolajczyk, Rafael T.
Greiner, Wolfgang
Wichmann, Ole
author_facet Damm, Oliver
Ultsch, Bernhard
Horn, Johannes
Mikolajczyk, Rafael T.
Greiner, Wolfgang
Wichmann, Ole
author_sort Damm, Oliver
collection PubMed
description BACKGROUND: A systematic review was conducted to assess the cost-effectiveness of routine varicella and herpes zoster (HZ) vaccination in high-income countries estimated by modelling studies. METHODS: A PubMed search was performed to identify relevant studies published before October 2013. Studies were included in the review if they (i) evaluated the cost-effectiveness of routine childhood or adolescent varicella vaccination and/or HZ vaccination targeting the elderly, and if they (ii) reported results for high-income countries. RESULTS: A total of 38 model-based studies were identified that fulfilled the inclusion criteria. Routine childhood or adolescent varicella vaccination was cost-effective or cost-saving from a payer perspective and always cost-saving from a societal perspective when ignoring its potential impact on HZ incidence due to reduced or absent exogenous boosting. The inclusion of the potential impact of childhood varicella vaccination on HZ led to net quality-adjusted life-year (QALY) losses or incremental cost-effectiveness ratios exceeding commonly accepted thresholds. Additional HZ vaccination could partially mitigate this effect. Studies focusing only on the evaluation of HZ vaccination reported a wide range of results depending on the selected target age-group and the vaccine price, but most found HZ vaccination to be a cost-effective or marginally cost-effective intervention. Cost-effectiveness of HZ vaccination was strongly dependent on the age at vaccination, the price of the vaccine, the assumed duration of protection and the applied cost per QALY threshold. CONCLUSIONS: While HZ vaccination is mostly considered cost-effective, cost-effectiveness of varicella vaccination primarily depends on the in- or exclusion of exogenous boosting in the model. As a consequence, clarification on the role of exogenous boosting is crucial for decision-making regarding varicella vaccination.
format Online
Article
Text
id pubmed-4455277
institution National Center for Biotechnology Information
language English
publishDate 2015
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-44552772015-06-05 Systematic review of models assessing the economic value of routine varicella and herpes zoster vaccination in high-income countries Damm, Oliver Ultsch, Bernhard Horn, Johannes Mikolajczyk, Rafael T. Greiner, Wolfgang Wichmann, Ole BMC Public Health Research Article BACKGROUND: A systematic review was conducted to assess the cost-effectiveness of routine varicella and herpes zoster (HZ) vaccination in high-income countries estimated by modelling studies. METHODS: A PubMed search was performed to identify relevant studies published before October 2013. Studies were included in the review if they (i) evaluated the cost-effectiveness of routine childhood or adolescent varicella vaccination and/or HZ vaccination targeting the elderly, and if they (ii) reported results for high-income countries. RESULTS: A total of 38 model-based studies were identified that fulfilled the inclusion criteria. Routine childhood or adolescent varicella vaccination was cost-effective or cost-saving from a payer perspective and always cost-saving from a societal perspective when ignoring its potential impact on HZ incidence due to reduced or absent exogenous boosting. The inclusion of the potential impact of childhood varicella vaccination on HZ led to net quality-adjusted life-year (QALY) losses or incremental cost-effectiveness ratios exceeding commonly accepted thresholds. Additional HZ vaccination could partially mitigate this effect. Studies focusing only on the evaluation of HZ vaccination reported a wide range of results depending on the selected target age-group and the vaccine price, but most found HZ vaccination to be a cost-effective or marginally cost-effective intervention. Cost-effectiveness of HZ vaccination was strongly dependent on the age at vaccination, the price of the vaccine, the assumed duration of protection and the applied cost per QALY threshold. CONCLUSIONS: While HZ vaccination is mostly considered cost-effective, cost-effectiveness of varicella vaccination primarily depends on the in- or exclusion of exogenous boosting in the model. As a consequence, clarification on the role of exogenous boosting is crucial for decision-making regarding varicella vaccination. BioMed Central 2015-06-05 /pmc/articles/PMC4455277/ /pubmed/26041469 http://dx.doi.org/10.1186/s12889-015-1861-8 Text en © Damm et al. 2015 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Research Article
Damm, Oliver
Ultsch, Bernhard
Horn, Johannes
Mikolajczyk, Rafael T.
Greiner, Wolfgang
Wichmann, Ole
Systematic review of models assessing the economic value of routine varicella and herpes zoster vaccination in high-income countries
title Systematic review of models assessing the economic value of routine varicella and herpes zoster vaccination in high-income countries
title_full Systematic review of models assessing the economic value of routine varicella and herpes zoster vaccination in high-income countries
title_fullStr Systematic review of models assessing the economic value of routine varicella and herpes zoster vaccination in high-income countries
title_full_unstemmed Systematic review of models assessing the economic value of routine varicella and herpes zoster vaccination in high-income countries
title_short Systematic review of models assessing the economic value of routine varicella and herpes zoster vaccination in high-income countries
title_sort systematic review of models assessing the economic value of routine varicella and herpes zoster vaccination in high-income countries
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4455277/
https://www.ncbi.nlm.nih.gov/pubmed/26041469
http://dx.doi.org/10.1186/s12889-015-1861-8
work_keys_str_mv AT dammoliver systematicreviewofmodelsassessingtheeconomicvalueofroutinevaricellaandherpeszostervaccinationinhighincomecountries
AT ultschbernhard systematicreviewofmodelsassessingtheeconomicvalueofroutinevaricellaandherpeszostervaccinationinhighincomecountries
AT hornjohannes systematicreviewofmodelsassessingtheeconomicvalueofroutinevaricellaandherpeszostervaccinationinhighincomecountries
AT mikolajczykrafaelt systematicreviewofmodelsassessingtheeconomicvalueofroutinevaricellaandherpeszostervaccinationinhighincomecountries
AT greinerwolfgang systematicreviewofmodelsassessingtheeconomicvalueofroutinevaricellaandherpeszostervaccinationinhighincomecountries
AT wichmannole systematicreviewofmodelsassessingtheeconomicvalueofroutinevaricellaandherpeszostervaccinationinhighincomecountries